Aprea Therapeutics Reports $3.9 Million Net Loss in Q1 2025, Seeks Additional Funding

Aprea Therapeutics, Inc. reported a net loss of $3.9 million for the first quarter of 2025, an increase from a net loss of $2.8 million during the same period in 2024. The company's grant revenue decreased to $162,463, down from $380,569 in the prior year, reflecting a decline in funding from government and non-government sources. Total operating expenses rose to $4.2 million, compared to $3.5 million in the previous year, primarily driven by increased research and development costs associated with ongoing clinical trials for its product candidates, APR-1051 and ATRN-119.

Research and development expenses surged to $2.5 million in the first quarter of 2025, up from $1.6 million in the same quarter of 2024. This increase was largely attributed to the initiation of the Phase 1 dose-escalation study for APR-1051 and the ongoing clinical trial for ATRN-119. General and administrative expenses slightly decreased to $1.8 million from $1.9 million, mainly due to reduced professional fees. The company’s cash and cash equivalents stood at $19.3 million as of March 31, 2025, down from $22.9 million at the end of 2024, indicating a need for additional funding to support ongoing operations.

Aprea Therapeutics has been actively pursuing its clinical programs, with APR-1051 and ATRN-119 as key candidates in its pipeline. The company is currently enrolling patients in clinical trials for both products, with expectations to report safety and efficacy data in the second half of 2025. The company is also exploring combination therapies with other agents to enhance the effectiveness of its product candidates. Despite these advancements, Aprea has acknowledged substantial doubt about its ability to continue as a going concern without additional funding, as its existing cash reserves are not expected to cover operational expenses for the next twelve months.

In terms of operational metrics, Aprea's employee headcount and customer engagement statistics were not disclosed in the filing. However, the company continues to focus on expanding its clinical development efforts and enhancing its intellectual property portfolio. Aprea's strategic initiatives include seeking collaborations and partnerships to bolster its financial position and expedite the development of its product candidates. The company remains committed to advancing its research and development activities while navigating the challenges of the biopharmaceutical landscape.